Additional information
Diabetes Clinical Research
The Diabetes Clinical Research Program at Benaroya Research Institute is an international leader in Type 1 (autoimmune) diabetes research. The program's goal is to help families with Type 1 diabetes by investigating ways to prevent diabetes, finding new approaches of diagnosing the disease in its earliest stage to optimize the potential for successful treatment, and testing innovative new therapies.
Commencement Bay Rowing Club teammates participate in Type 1 diabetes research at BRI
Type 1 Diabetes TrialNet, Northwest Clinical Center
The Diabetes Clinical Research Program at Benaroya Research Institute is the Type 1 Diabetes TrialNet Northwest Clinical Center. TrialNet is a network of 18 clinical centers located worldwide. As the Northwest Clinical Center, the Diabetes Program coordinates with sites in Washington, Idaho, Oregon, Montana and Alaska to conduct prevention research for persons at risk for Type 1 diabetes and to study intervention therapies for children and adults with newly diagnosed diabetes. The TrialNet clinical centers are working toward the goal of screening 200,000 relatives of persons with Type 1 diabetes to determine their risk and to increase scientific knowledge about Type 1 diabetes. Individuals found to be at risk will be closely monitored and may be eligible for prevention trials. www.diabetestrialnet.org.
Immune Tolerance Network, Clinical Center
The Diabetes Clinical Research Program is a member of the Immune Tolerance Network (ITN), a collaborative research effort aimed at inducing, maintaining and monitoring tolerance in humans, for kidney, liver and islet transplantation, autoimmune diseases and allergy and asthma. We are currently conducting studies aimed at preserving insulin secretion in patients newly diagnosed with Type 1 diabetes. www.immunetolerance.org.
JDRF-BRI Center for Translational Research
The Diabetes Research Program is designated as the Juvenile Diabetes Research Foundation (JDRF) Center for Translational Research. The goal is to combine the clinical, metabolic, genetic and immune information from persons with Type 1 diabetes and their family members to better understand the Type 1 diabetes disease process.